Nov 15, 2022 · Conclusion: This randomized trial demonstrates that SCT is superior to non-SCT consolidation treatment for LFS in elderly AML patients in CR1 on ...
... AlloSCT, particularly with reduced intensity conditioning prolongs overall survival compared to conventional therapy in patients older than 60 years of age, ...
People also ask
What is the most serious complication of hematopoietic stem cell transplant?
What is the most common cause of death in hematopoietic stem cell transplant?
Does donor age affect outcome after allogeneic hematopoietic cell transplantation?
What is CR1 and CR2 in AML?
Dec 10, 2023 · In this high-risk population, disease-free survival was 25.2% after 5 years and 18.7% after 10 years, while overall survival rates were 29.8% ...
It indicates that alloHCT led to heightened early risks from TRM, yet reduced relapse and superior long-term survival relative to CT in older AML patients in ...
Missing: Matched Donor Randomized
Their reported outcomes were 63% 2-year OS, 29% 1-year RI, and 17% 1-year NRM. Allo-HCT offers a potential cure in a subset of patients with PIF AML. However, ...
Research shows older AML patients in first complete remission have better outcomes with allogeneic HCT than non-transplant conventional consolidation ...
Missing: Increased | Show results with:Increased
Retrospective and observational studies have shown improved survival with allo-HCT compared to CC in older patients with AML [56, 57, 58]. However, such studies ...
Aug 28, 2023 · The 2-year OS and LFS were 79% and 61% respectively, in the intermediate-risk MRD-negative category, and 70% and 67% respectively, in the MRD ...
Missing: Increased | Show results with:Increased
Jan 7, 2016 · With a mature follow-up of more than 5 years, the actual rates of relapse after chemotherapy vs after autoHSCT were 70% vs 58%, respectively (P ...
Aug 8, 2024 · The primary outcome RM-LFS up to 5 years was 24.5 months (95%CI:18.9-30.1) in the HCT and 15.6 months (95%CI:10.4-20.8) in the non-HCT arm (p= ...
